Although the aberrant expression of DUX4 has been predominantly studied in the context of FSHD, recent studies have demonstrated that DUX4 is ectopically expressed in various cancers and plays a critical role in tumor progression, immune evasion, and therapy resistance. This evidence concerns the gene DUX4 and neoplasm.